With the development of nano-delivery systems and molecular imaging technologies, the integrated diagnostic and therapeutic solutions targeting the NPR family are expected to become a new breakthrough point in precision medicine for tumors, however, special attention must be paid to the variability of receptor functions in different tumor types to avoid generalizing therapeutic targets. This evidence concerns the gene NPTXR and neoplasm.